**Author details**

Sara Karaki, Clément Paris and Palma Rocchi\* CRCM: Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France

\*Address all correspondence to: palma.rocchi@inserm.fr

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**25**

*Antisense Oligonucleotides, A Novel Developing Targeting Therapy*

[9] Disterer P, Kryczka A, Liu Y, Badi YE, Wong JJ, Owen JS, et al. Development of therapeutic splice-switching

oligonucleotides. Human Gene Therapy.

2014 Jul;**25**(7):587-598

[10] Chan JH, Lim S, Wong WS. Antisense oligonucleotides: From design to therapeutic application. Clinical and Experimental

Pharmacology & Physiology. 2006

[11] Sohail M, Southern EM. Selecting optimal antisense reagents. Advanced

May-Jun;**33**(5-6):533-540

Drug Delivery Reviews. 2000

[12] Cho YS, Kim MK, Cheadle C, Neary C, Becker KG, Cho-Chung YS. Antisense DNAs as multisite genomic modulators identified by DNA microarray. Proceedings of the National Academy of Sciences of the United States of America. 2001

[13] Ho SP, Bao Y, Lesher T, Malhotra R, Ma LY, Fluharty SJ, et al. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nature Biotechnology. 1998

molecules. Journal of Molecular Biology.

[15] Vickers TA, Wyatt JR, Freier SM. Effects of RNA secondary structure on cellular antisense activity. Nucleic Acids Research. 2000 Mar;**28**(6):1340-1347

[16] Ding Y, Lawrence CE. Statistical prediction of single-stranded regions in RNA secondary structure and application to predicting effective antisense target sites and beyond.

[14] Andronescu M, Zhang ZC, Condon A. Secondary structure prediction of interacting RNA

2005 Feb;**345**(5):987-1001

Oct;**44**(1):23-34

Aug;**98**(17):9819-9823

Jan;**16**(1):59-63

*DOI: http://dx.doi.org/10.5772/intechopen.82105*

[1] Sridharan K, Gogtay NJ. Therapeutic

[2] Cavagnari BM. Gene therapy: Nucleic acids as drugs. Action mechanisms and delivery into the cell. Archivos Argentinos de Pediatría. 2011 Jun;

[3] Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proceedings of the National Academy of Sciences of the United States of America. 1978 Jan;**75**(1):280-284

[4] Grillone LR, Lanz R. Fomivirsen. Drugs Today (Barc). 2001 Apr;**37**(4):245-255

[5] Wong E, Goldberg T. Mipomersen

(kynamro): A novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia. Pharmacy and Therapeutics. 2014

[6] Bennett CF, Swayze EE. RNA targeting therapeutics: Molecular

oligonucleotides as a therapeutic platform. Annual Review of Pharmacology and Toxicology.

[7] Wu H, Lima WF, Zhang H, Fan A, Sun H, Crooke ST. Determination of the role of the human RNase H1 in the pharmacology of DNAlike antisense drugs. The Journal of Biological Chemistry. 2004 Apr;**279**(17):17181-17189

[8] Kole R, Krainer AR, Altman S. RNA therapeutics: Beyond RNA interference

and antisense oligonucleotides. Nature Reviews. Drug Discovery. 2012

Feb;**11**(2):125-140

mechanisms of antisense

Feb;**39**(2):119-122

2010;**50**:259-293

nucleic acids: Current clinical status. British Journal of Clinical Pharmacology. 2016 Sep;**82**(3):659-672

**109**(3):237-244

**References**

*Antisense Oligonucleotides, A Novel Developing Targeting Therapy DOI: http://dx.doi.org/10.5772/intechopen.82105*
